Endpoints News 27. Feb. 2026 Novo Nordisk’s ‘strategic conundrum’: How being anchored to the past could cost it the future
Endpoints News 26. Feb. 2026 Doug Ingram’s force of will meets its match as Sarepta CEO plans to depart
Endpoints News 26. Feb. 2026 Boehringer wins accelerated approval for first-line use of lung cancer drug
Endpoints News 26. Feb. 2026 Viatris plans to lay off up to 10% of staff, discloses Indian factory fire
Endpoints News 26. Feb. 2026 AtaiBeckley stock drops on Phase 2a data; Disc to refile rare disease drug
Endpoints News 26. Feb. 2026 Protagonist to opt out of Takeda profit-sharing deal, will receive $400M in cash
Endpoints News 26. Feb. 2026 Novartis to build another radioligand factory; Germany steps up probe into Gerresheimer
Endpoints News 26. Feb. 2026 OrbiMed jumps to number one on the top 100 list of biotech venture investors
Endpoints News 26. Feb. 2026 Lilly's GLP-1 pill beats Novo’s in diabetes trial, has more side effects